Similar companies
Income Statement (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Revenue | 730,000 | 48.8% |
| Gross Profit | -3.5M | 9.2% |
| Cost of Revenue | 4.2M | 14.4% |
| Operating expense | 8.4M | 0.7% |
| Net Income | -7.5M | 1.1% |
| EBITDA | -7.6M | 2.3% |
Balance Sheet (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Total Assets | 17M | 18.2% |
| Total Liabilities | 13M | 13.2% |
| Total Equity | 4.9M | 52.2% |
| Shares Outstanding | 8.6M | 6.5% |
Cash Flow (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Cash from operations | -5M | 21.5% |
| Cash from financing | 1.7M | 0% |
EPS
Financial Highlights for Lumos Pharma in Q3 '24
Lumos Pharma reported a revenue of 730,000, which is a 48.8% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at -3.5M, marking a -9.2% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 4.2M, a 14.4% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 8.4M, showing a 0.7% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -7.5M, showing a 1.1% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -7.6M, showing a 2.3% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
Lumos Pharma faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. Higher operating expenses might indicate increased investments or potential inefficiencies.
